Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Teams Up with Ortho-Clinical to Turn Biomarkers into Dx

NEW YORK, June 8 (GenomeWeb News) - Compugen and Ortho-Clinical Diagnostics, a Johnson & Johnson company, will jointly develop diagnostic tests based on Compugen's biomarkers, the Tel Aviv-based company said today.

 

Initially, Ortho-Clinical will have the option to select up to nine biomarkers that the partners will clinically validate. Following successful validation, Ortho-Clinical plans to develop markers into products. In exchange for paying development milestones and revenue-based royalties, Ortho-Clinical will have worldwide rights to commercialize the tests. Compugen will also receive license fees for each commercialized biomarker.

 

Compugen discovered the biomarkers using its LEADS platform, which analyzes the human proteome.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.